{"product_id":"biolegend-502511","title":"Biolegend, 502511, APC anti-human IFN-γ Antibody, 25tests","description":"\u003cp\u003eInterferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.\u003cbr\u003e\n25tests\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Partially purified, native human IFN-γ\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402\/502404) or purified MD-1 antibody (Cat. No. 507502\/507513) as the capture antibody.Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)\u003cbr\u003e\nProduct Citations: Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed Li M, et al. 2021. J Clin Invest. 131:. PubMed Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed Swadling L, et al. 2022. Nature. 601:110. PubMed McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed Peng W, et al. 2023. Cells. 12: . PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Veatch JR, et al. 2022. Cancer Cell. 40:393. PubMed Goetzmann J, et al. 2014. Proc Natl Acad Sci U S A. 111:8873. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed Devalraju KP, et al. 2021. PLoS One. 16:e0257185. PubMed Chandran A, et al. 2022. Cell Rep Med. 3:100557. PubMed Su W, et al. 2022. Front Immunol. 13:952338. PubMed Pandey A, et al. 2020. Nat Commun. 3.392361111. PubMed Norian L, et al. 2009. Cancer Res. 69:3086. PubMed Harshe RP, et al. 2020. Nat Commun. 11:5894. PubMed Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed Longhi M, et al. 2014. PLoS One. 9:87956. PubMed Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Cai J, et al. 2021. eLife. 10:00. PubMed Baban B, et al. 2021. JCI Insight. 6:00. PubMed Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Draganov DD, et al. 2019. J Transl Med. 17:100. PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed Guo S, et al. 2021. Stem Cells Int. 2021:9989790. PubMed Zhang X, et al. 2017. J Immunol. 10.4049\/jimmunol.1602183. PubMed Du Q, et al. 2018. J Immunol. 201:533. PubMed Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed Liu W, et al. 2022. Bio Protoc. 12:e4285. PubMed Roybal KT et al. 2016. Cell. 167(2):419-432 . PubMed Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed Tian X, et al. 2015. J Immunol. 194:3873. PubMed Yang C, et al. 2019. Nat Commun. 10:3931. PubMed Shen C, et al. 2021. BMC Med. 19:283. PubMed Tesch S, et al. 2020. Sci Rep. 10:21312. PubMed\u003cbr\u003e\nRRID: AB_315236 (BioLegend Cat. No. 502511) AB_315237 (BioLegend Cat. No. 502512)\u003cbr\u003e\nStructure: Cytokine; dimer; 20-25 kD (Mammalian)\u003cbr\u003e\nBioactivity: Antiviral\/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.\u003cbr\u003e\nRegulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2\u003cbr\u003e\nGene ID: 3458\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nClone: 4S.B3\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862419722409,"sku":"502511","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-502511","provider":"Iright","version":"1.0","type":"link"}